Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients

Diabetes Research and Clinical Practice

Volumn 98, Issue 1, 2012, Pages 51-60

  Derosa, Giuseppe ^a   Carbone, Anna ^b   Franzetti, Ivano ^c   Querci, Fabrizio ^d   Fogari, Elena ^a   Bianchi, Lucio ^a   Bonaventura, Aldo ^a   Romano, Davide ^a   Cicero, Arrigo F G ^e   Maffioli, Pamela ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b Hospital Center of Diabetes   (Italy)

^c OSPEDALE DI CIRCOLO   (Italy)

^d Ospedale Pesenti Fenaroli   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Clamp; HOMA ; Inflammation; Insulin resistance; Metformin; Sitagliptin

Indexed keywords

ADIPONECTIN; ARGININE; C PEPTIDE; C REACTIVE PROTEIN; GLUCAGON; METFORMIN; PLACEBO; PROINSULIN; SITAGLIPTIN;

ADULT; ARTICLE; B LYMPHOCYTE; BODY MASS; CELL FUNCTION; CONTROLLED STUDY; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; EXERCISE; FEMALE; GLUCAGON BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; ITALY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; WEIGHT REDUCTION;

BLOOD GLUCOSE; C-PEPTIDE; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EXERCISE; FASTING; FEMALE; GLUCAGON; GLUCOSE CLAMP TECHNIQUE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; ITALY; MALE; METFORMIN; MIDDLE AGED; PYRAZINES; TREATMENT OUTCOME; TRIAZOLES;

EID: 84867400778     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2012.05.022     Document Type: Article

References (47)

1. DeFronzo R.A. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988, 37:667-687.
2. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009, 52:17-30.
3. Setter S.M., Iltz J.L., Thams J., Campbell R.K. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy. Clin Ther 2003, 25:2991-3026.
4. Garber A.J., Donovan D.S., Dandona P., Bruce S., Park J.S. Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. J Clin Endocrinol Metab 2003, 88:3598-3604.
5. Deeks E.D., Scott L.J. Pioglitazone/metformin. Drugs 2006, 66:1863-1877.
6. Derosa G., Maffioli P. Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes. Diabetes Metab Syndr Obes 2011, 4:263-271.
7. DeFronzo R.A., Goodman A.M. Efficacy of metformin in patients with noninsulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995, 333:541-549.
8. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854-865.
9. Turner R.C., Cull C.A., Fighi V., Holman R.R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies. UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999, 281:2005-2012.
10. Barnard K., Cox M.E., Green J.B. Clinical utility of fixed combinations of sitagliptin-metformin in treatment of type 2 diabetes. Diabetes Metab Syndr Obes 2010, 3:363-372.
11. Nauck M.A., Meininger G., Sheng D., Terranella L., Stein P.P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007, 9:194-205.
12. Brazg R., Xu L., Dalla M.C., Cobelli C., Thomas K., Stein P.P. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diabetes Obes Metab 2007, 9:186-193.
13. Xu L., Man C.D., Charbonnel B., Meninger G., Davies M.J., Williams-Herman D., et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach. Diabetes Obes Metab 2008, 10(12):1212-1220.
14. Derosa G., Maffioli P. DPP-4 inhibitors: three years of experience. Diabetes Technol Ther 2012, 14(4):350-364.
15. Aschner P., Katzeff H.L., Guo H., Sunga S., Williams-Herman D., Kaufman K.D., et al. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab 2010, 12(3):252-261.
16. Reasner C., Olansky L., Seck T.L., Williams-Herman D.E., Chen M., Terranella L., et al. The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2011, 13(7):644-652.
17. Hermansen K., Kipnes M., Luo E., Fanurik D., Khatami H., Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007, 9(5):733-745.
18. Derosa G., Maffioli P., Salvadeo S.A., Ferrari I., Ragonesi P.D., Querci F., et al. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism 2010, 59(6):887-895.
19. Vilsbøll T., Rosenstock J., Yki-Järvinen H., Cefalu W.T., Chen Y., Luo E., et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2010, 12(2):167-177.
20. Migoya E.M., Bergeron R., Miller J.L., Snyder R.N., Tanen M., Hilliard D., et al. Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther 2010, 88(6):801-808.
21. Charbonnel B., Karasik A., Liu J., Wu M., Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006, 29(12):2638-2643. Sitagliptin Study 020 Group.
22. Scott R., Loeys T., Davies M.J., Engel S.S. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008, 10(10):959-969. Sitagliptin Study 801 Group.
23. Raz I., Chen Y., Wu M., Hussain S., Kaufman K.D., Amatruda J.M., et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin 2008, 24(2):537-550.
24. Williams-Herman D., Xu L., Teng R., Golm G.T., Johnson J., Davies M.J., et al. Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes. Diabetes Obes Metab 2012, 14(1):67-76.
25. Ward W.K., Bolgiano D.C., McKnight B., Halter J.B., Porte D. Diminished beta-cell secretory capacity in patients with non insulin dependent diabetes mellitus. J Clin Invest 1984, 74:1318-1328.
26. Rydén L., Standl E., Bartnik M., Van den Berghe G., Betteridge J., de Boer M.J., et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur Heart J 2007, 28(1):88-136.
27. Lichtenstein A.H., Appel L.J., Brands M., Carnethon M., Daniels S., Franch H.A., et al. Summary of American Heart Association Diet and Lifestyle Recommendations Revision 2006. Arterioscler Thromb Vasc Biol 2006, 26:2186-2191.
28. Bunn H.F., Gabbay K.H., Gallop P.M. The glycosylation of haemoglobin. Relevance to diabetes mellitus. Science 1978, 200:21-27.
29. European Diabetes Policy Group A desktop guide to type 2 diabetes mellitus. Diabet Med 1999, 16:716-730.
30. Heding L.G. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 1972, 8:260-266.
31. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
32. Wallace T.M., Levy J.C., Matthews D.R. Use and abuse of HOMA modeling. Diabetes Care 2004, 27:1487-1495.
33. Houssa P., Dinesen B., Deberg M., Frank B.H., Van Schravendijk C., Sodoyez-Goffaux F., et al. First direct assay for intact human proinsulin. Clin Chem 1998, 44(7):1514-1519.
34. El Kenz H., Bergmann P. Evaluation of immunochemiluminometric assays for the measurement of insulin and C-peptide using the ADVIA Centaur. Clin Lab 2004, 50:171-174.
35. Holst J.J. Evidence that peak I.I. GLI or enteroglucagon is identical to the C-terminal sequence (residues 33-69) of glicentin. Biochem J 1982, 207:381-388.
36. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001, 7:941-946.
37. Rifai N., Tracy R.P., Ridker P.M. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999, 45(12):2136-2141.
38. DeFronzo R.A., Tobin J.D., Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979, 237:E214-E223.
39. Bunck M.C., Diamant M., Corner A., Eliasson B., Malloy J.L., Shaginian R.M., et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009, 32:762-768.
40. Fasching P., Ratheiser K., Nowotny P., Uurzemann S., Parker S., Waldhaus W. Insulin production following intravenous glucose, arginine, and valine: different pattern in patients with impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Metabolism 1994, 43:385-389.
41. Winer B.J. Statistical principles in experimental design 1971, McGraw-Hill, New York. 2nd ed.
42. Kubota A., Matsuba I., Saito T., Nabe K., Seino Y. Secretory units of islets in transplantation index is a useful clinical marker to evaluate the efficacy of sitagliptin in treatment of type 2 diabetes mellitus. J Diabetes Invest 2011, 2:377-380.
43. Yoon K.H., Shockey G.R., Teng R., Golm G.T., Thakkar P.R., Meehan A.G., et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes. Int J Clin Pract 2011, 65(2):154-164.
44. Herman G.A., Bergman A., Stevens C., Kotey P., Yi B., Zhao P., et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006, 91:4612-4619.
45. Zwacka T.P., Hornbach V., Torzewski J. C-reactive protein-mediated lipoprotein uptake by macrophages. Circulation 2001, 103:1194-1197.
46. Jackson M.B., Ahima R.S. Neuroendocrine and metabolic effects of adipocyte-derived hormones. Clin Sci 2006, 110:143-152.
47. Derosa G., Ragonesi P.D., Carbone A., Fogari E., Bianchi L., Bonaventura A., et al. Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients. Diabetes Technol Ther 2012, in press. 10.1089/dia.2011.0278.